Navelbine® and Taxotère® : Histories of Sciences

Autor: Muriel Le Roux, Françoise Gueritte

Among the many forms of cancer treatment, chemotherapy remains an important part of the arsenal in which Navelbine and Taxotere play a major role.These medicines result from molecules discovered by French researchers of the Institut de Chimie des Sub

Cytotoxic effects of hyperthermia, chemotherapy (Navelbine) and radiation on glioma spheroids

Autor: Mahdavi, Seied Rabi, Yahyapour, Rasoul, Nikoofar, Alireza

Publikováno v: In Radiation Physics and Chemistry June 2016 123:20-24

Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine.

Autor: Gachechiladze, Mariam¹ (AUTHOR), Tichý, Tomáš¹ (AUTHOR), Kolek, Vítězslav² (AUTHOR), Grygárková, Ivona² (AUTHOR), Klein, Jiří³ (AUTHOR), Mgebrishvili, Giorgi¹ (AUTHOR), Kharaishvili, Gvantsa¹ (AUTHOR), Janíková, Mária¹ (AUTHOR), Smičková, Petra² (AUTHOR), Cierna, Lucia⁴ (AUTHOR), Pitson, Stuart⁵ (AUTHOR), Maddelein, Marie-Lise⁶ (AUTHOR), Cuvillier, Olivier^6,7 (AUTHOR) olivier.cuvillier@inserm.fr, Škarda, Jozef¹ (AUTHOR) jojos@email.cz

Publikováno v: Oncology Letters. Aug2019, Vol. 18 Issue 2, p1259-1266. 8p.

375P Results from the Danish Breast Cancer Group's (DBCG) NAME-trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic breast cancer

Autor: Brems-Eskildsen, A.S., Kenholm, J., Brixen, A.T.L., Rønlev, J.D., Stenbygaard, L.E., Danoe, H., Grunnet, M., Jakobsen, E.H., Neimann, J., Geisler, J., Glavicic, V., Langkjer, S.T.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S376-S376

The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer

Autor: T. Dongsgaard, Sven Tyge Langkjer, Lars Stenbygaard, Helle Lemvig Kruse, Julia Kenholm, Anne Sofie Brems-Eskildsen, Jeanette Dupont Jensen, Hella Danø, Bjørnar Gilje, Kim Wedervang, J. Neimann, Jürgen Geisler, Erik Hugger Jacobsen, Vesna Glavicic, Mie Grunnet, Annette Torbøl Brixen

Publikováno v: Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : A direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124

Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd3e68144dbea7113137cab419868c36
http://hdl.handle.net/10852/77735